Jessica Fye
Stock Analyst at JP Morgan
(1.61)
# 1408
Out of 5,333 analysts
227
Total ratings
53.70%
Success rate
5.84%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
VRTX Vertex Pharmaceuticals | Maintains: Overweight | 512 515 | 425.2 | 21.12% | 8 | May 6, 2025 | |
BCRX BioCryst Pharma | Maintains: Overweight | 10 13 | 9.98 | 30.26% | 4 | May 6, 2025 | |
ASND Ascendis Pharma | Maintains: Overweight | 200 245 | 151.46 | 61.76% | 11 | May 2, 2025 | |
UTHR United Therapeutics | Maintains: Overweight | 355 350 | 301.32 | 16.16% | 13 | May 1, 2025 | |
INCY Incyte | Maintains: Neutral | 70 68 | 59.01 | 15.23% | 6 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 55 58 | 65.86 | -11.93% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 311 317 | 231.63 | 36.86% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 54 50 | 28.38 | 76.18% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 29 28 | 17.36 | 61.29% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 47 45 | 32.3 | 39.32% | 4 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 280 328 | 251.55 | 30.39% | 5 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 40 33 | 24.25 | 36.08% | 12 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 200 209 | 97.82 | 113.66% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 83 92 | 65.17 | 41.17% | 7 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 24 | 14.39 | 66.78% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 124 122 | 92.85 | 31.39% | 10 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 81 89 | n/a | n/a | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 110 109 | 58.88 | 85.12% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 32 26 | 30.16 | -13.79% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 200 235 | n/a | n/a | 4 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | 11.11 | 170.03% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 47 54 | 30.7 | 75.9% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 31 39 | 44.32 | -12% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 6 13 | 9.35 | 39.04% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 14 16 | n/a | n/a | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 25 45 | n/a | n/a | 4 | Dec 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 217 330 | n/a | n/a | 1 | Dec 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Underweight | n/a | n/a | n/a | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Underweight | n/a | n/a | n/a | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | n/a | n/a | n/a | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Underweight | n/a | n/a | n/a | 3 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | n/a | n/a | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 76 | 31.76 | 139.29% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 154 150 | n/a | n/a | 2 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 4 | Oct 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 612 720 | n/a | n/a | 2 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 150 70 | n/a | n/a | 2 | Jan 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 256 112 | n/a | n/a | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 3 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22 | 1.27 | 1632.28% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 7 | 0.7 | 900% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 32 27 | 29.34 | -7.98% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 9 8 | n/a | n/a | 4 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 9 8 | n/a | n/a | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 58 | n/a | n/a | 2 | Jan 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 4 | Feb 14, 2018 |